Trial Profile
Dolutegravir in Pregnant HIV Mothers and Their Neonates
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Efavirenz
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms DolPHIN-2
- 06 Mar 2024 Results presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
- 06 Mar 2024 Results of secondary analysis of this study presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
- 10 Nov 2023 Status changed from active, no longer recruiting to completed.